News | Artificial Intelligence | August 16, 2022

Dyad Medical Secures FDA Clearance For Echo: Prio Cardiac Imaging Analysis Platform

Libby’s AI and cloud-based technology aids Echocardiogram image analysis 

Libby’s AI and cloud-based technology aids Echocardiogram image analysis

August 16, 2022 — Dyad Medical, Inc., the developer of the cloud-based AI technology for cardiac image analysis, announced that the U.S. Food and Drug Administration (FDA) has cleared its Echocardiogram application called Echo:Prio through the 510(k) pathway.  Echo:Prio , part of the complete cardiac platform named Libby, offers fast, data-driven image analysis of echocardiogram images. It is an important decision-making support tool for index quantification of cardiac function saving the clinician time in diagnosis and treatment-decision making. 

Echocardiograms are often the first step in diagnosing and developing a treatment plan for heart disease. The heart is the only organ in constant movement as it pumps blood throughout the body. When analyzing the left ventricle, any abnormal motion may be a sign of heart disease. Most imaging labs rely on visual detections of these abnormalities to diagnose and manage heart disease. This subjective process requires a complete view of the endocardium which is not always available. Furthermore, additional factors influencing image interpretations include operator skill level and variations in heart rates and cardiac loading, all of which may be addressed using automated analysis. 

“The current process of manual echocardiographic assessment of myocardial function is time consuming and lacks consistency between readings. The FDA’s clearance of Dyad Medical’s Echo:Prio application allows us to provide operators and physicians an essential computer-assisted tool for echocardiographic analysis. Our solution is proven to be consistent and can be used across all systems, regardless of an operator’s skill level,” said Dr. Ronny Shalev, CEO and co-Founder of Dyad Medical, Inc. 

Libby Echo:Prio is embedded in the current workflow of imaging operators, physicians, and researchers. The Libby platform is cloud-based, offering users a secure way to use it from any location on any device. The AI-powered platform provides users an immediately-available second opinion when diagnosing cardiac images saving them critical time that can be spent with patients. 

“Dyad Medical’s Echo:Prio application allows physicians to prioritize patient treatments and deliver the life-saving care needed for those who need it most,” said Shalev. “Echocardiogram analysis done manually is time consuming and must be done consistently across all patients and operators. Echo:Prio is expanding the physician’s view so they have greater confidence in their diagnosis leading to greater patient satisfaction and retention.”  

This is the second FDA clearance Dyad Medical has received for its Libby cardiac imaging analysis platform. Dyad Medical’s intravascular optical coherence tomography application is also FDA cleared. Focusing on AI-powered analysis of cardiac images, the company continues to enhance its applications for other imaging modalities.  

For more information: www.dyadmedical.com 


Related Content

Videos | Cardiac Imaging

Artificial intelligence and general consolidation were two top cardiology trends at RSNA22. ITN/DAIC spoke with Val ...

Home January 23, 2023
Home
News | Cardiac Imaging

January 13, 2023 — Nuclear stress testing performed with single-photon emission computed tomography (SPECT) is the most ...

Home January 13, 2023
Home
News | Cardiac Imaging

November 29, 2022 — Researchers have developed a deep learning model that uses a single chest X-ray to predict the 10 ...

Home November 29, 2022
Home
News | Cardiac Imaging

November 28, 2022 – UltraSight, an Israeli-based digital health pioneer transforming cardiac imaging through the power ...

Home November 28, 2022
Home
News | Cardiac Imaging

November 28, 2022 — Konica Minolta Healthcare Americas, Inc., a leader in medical diagnostic imaging and healthcare ...

Home November 28, 2022
Home
Feature | Cardiac Imaging

Discover the key features of cardiovascular structured reporting that drive adoption, including automated data flow, EHR ...

Home November 07, 2022
Home
News | Cardiac Imaging

October 18, 2022 — HeartFlow, Inc., a leader in revolutionizing precision heart care, has received U.S. Food and Drug ...

Home October 18, 2022
Home
Webinar | Cardiac Imaging

The direct impact of COVID-19 is substantial. The resulting impact of the pandemic has forced healthcare organizations ...

Home October 17, 2022
Home
News | Cardiac Imaging

October 11, 2022 — Researchers from the University of Minnesota Medical School found that patients with certain features ...

Home October 11, 2022
Home
News | Cardiac Imaging

September 2, 2022 — A randomized trial in more than 45,000 men has suggested that cardiovascular screening including ...

Home September 02, 2022
Home
Subscribe Now